January 31, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
OncoTherapy Science to Start Clinical Trials of OTS102 Angiogenesis Inhibitor

Tokyo, Apr 5, 2005 (JCN) - OncoTherapy Science announced on April 4 that the company has decided to start clinical trials of OTS102, an angeiogensis inhibitor for cancer treatment. The company plans to begin a Phase I clinical trial within fiscal 2005.

OTS102, which consists of VEGF-R2 protein, can inhibit blood vessels from growing from surrounding tissues to a solid tumor. The anticancer effect of OTS102 has been confirmed in animal experiments.

By Aki Tsukioka Contributor

Copyright © 2015 JCN. All rights reserved. A division of Japan Corporate News Network KK.

 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  OncoTherapy Science, Inc. News  
  OncoTherapy Science, Fuso Pharmaceutical Industries Jointly Undertake Phase I Clinical Trial of Anglogenesis Inhibitor OTS102  (Mar 31, 2006)
  OncoTherapy Science, Carna Biosciences, CrystalGenomics to Collaborate in Development of Low-molecular Drug for Cancer  (Feb 1, 2006)
  OncoTherapy Science, BioWa to Collaborate in Antibody Drug Development  (Oct 25, 2005)
  Medical & Biological Laboratories to Start Clinical Trials of Two Different ELISA Reagents for Serological Diagnosis  (June 27, 2005)
  OncoTherapy Science to Start Clinical Trials of OTS102 Angiogenesis Inhibitor  (Apr 5, 2005)
  Onco Therapy Science, Institute for Antibodies Conclude Licensing Agreement for Anticancer Antibody  (Apr 4, 2005)
  OncoTherapy Science (OTS), BioWa to Join Hands in Antibody Drug Development  (Aug 10, 2004)
  MBL, OncoTherapy Science to Establish Joint Venture for Antibody Drug Business  (Aug 4, 2004)

CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)